0.26  0.26 (0%)		09-17 16:00
Open: High: 0.26 Volume: 0		Pre. Close: Low: 0.26 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	0.23	1-year :	0.27
Resists	First :	0.2	Second :	0.23
Pivot price	0.17
Supports	First :	0.17	Second :	0.15
MAs	MA(5) :	0.17	MA(20) :	0.17
	MA(100) :	0.17	MA(250) :	0.36
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	66.9	D(3) :	52.9
RSI	RSI(14): 69.2
52-week	High :	1.58	Low :	0.14

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VYNT ] has closed above the upper band by 23.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 27.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.2 - 0.2	0.2 - 0.2
Low:	0.17 - 0.17	0.17 - 0.17
Close:	0.19 - 0.19	0.19 - 0.2

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Tue, 26 Dec 2023
Vyant Bio Provides Update on Winddown Activities - GlobeNewswire

Tue, 24 Oct 2023
Vyant Bio Announces Completion of StemoniX Asset Sale - Yahoo Finance

Fri, 12 May 2023
Vyant Bio Announces Last Day of Trading on Nasdaq and - GlobeNewswire

Wed, 23 Mar 2022
Vyant Bio (NASD: VYNT) is on the Cutting Edge of Biotech Drug Development - The Wall Street Transcript

Fri, 18 Mar 2022
Roberts, Jay - The Wall Street Transcript

Tue, 01 Mar 2022
Vyant Bio Issues Letter to Shareholders - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	6 (M)
Held by Insiders	5.1e+006 (%)
Held by Institutions	18.7 (%)
Shares Short	179 (K)
Shares Short P.Month	0 (K)

EPS	-1.328e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	400 %
Return on Equity (ttm)	-51.8 %
Qtrly Rev. Growth	397000 %
Gross Profit (p.s.)	-49.83
Sales Per Share	-218.59
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0.15

Dividend	0
Forward Dividend	204710
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.